2025-07-13 - Analysis Report
Okay, here's a report summarizing the provided data for Recursion Pharmaceuticals Inc. (RXRX), presented in English with numerical data and accompanying analysis.

## RXRX Stock Analysis: Recursion Pharmaceuticals Inc.

**Company Overview:** Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company leveraging artificial intelligence to discover and develop novel therapeutics.

### 1. Performance Relative to S&P 500 (VOO)

*   **RXRX Cumulative Return:** -51.14%
*   **VOO Cumulative Return:** 34.56%
*   **Spread (RXRX - VOO):** -82.4 (Current), Max: 35.8, Min: -88.1
*   **Relative Spread Percentile:** 4.6

**Analysis:** RXRX has significantly underperformed the S&P 500 (VOO) over the analyzed period. The current spread of -82.4 indicates a substantial lag. The relative spread percentile of 4.6 suggests that the current underperformance is near the worst observed in the historical data, meaning the stock has rarely performed worse relative to the S&P 500.

**Alpha, Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2021-2023  | 5.0% | 73.6% | -1.0% | -0.1 | 4.3 |
| 2022-2024  | 0.0% | 73.6% | -25.0% | 0.1 | 2.9 |
| 2023-2025  | 0.0% | 73.6% | -47.0% | 0.1 | 2.3 |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate is very low, especially in recent periods, suggesting minimal growth.
*   **MDD:** The Maximum Drawdown is consistently very high, indicating significant risk and volatility.
*   **Alpha:** The negative Alpha values indicate that RXRX has consistently underperformed relative to its risk-adjusted expected return. The Alpha is increasingly negative, suggesting worsening underperformance.
*   **Beta:** The Beta values are close to zero, implying that the stock's price movements are not strongly correlated with the market.
*   **Cap(B):** The market capitalization has decreased over the periods, suggesting a reduction in the company's market value.

### 2. Recent Stock Price Movements

*   **Last Price:** $5.28
*   **Previous Close:** $5.715
*   **Change:** -7.61%
*   **5-day Moving Average:** 5.375
*   **20-day Moving Average:** 5.1635
*   **60-day Moving Average:** 4.9836

**Analysis:** The stock experienced a significant price drop of -7.61% in the last trading session.  The current price is below the 5-day moving average, suggesting a short-term downward trend. However, it is above the 20-day and 60-day moving averages, potentially indicating some underlying support.

### 3. Technical Indicators and Expected Return

*   **Market Risk Indicator (MRI):** 0.3294 (Low Risk)
*   **RSI:** 54.08
*   **PPO:** 0.5258
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (1 shares - Caution - MRI:0.34)
*   **Recent (20-day) Relative Spread Change:** 3.2 (+) – Short-term increase
*   **Expected Return:** -536%

**Analysis:**

*   **MRI:** The Market Risk Indicator is in the "Low Risk" range.
*   **RSI:** The Relative Strength Index (RSI) of 54.08 is near neutral, not indicating overbought or oversold conditions.
*   **PPO:** The Percentage Price Oscillator (PPO) is slightly positive, indicating a minor upward trend.
*   **Hybrid Signal:** Suggests a cautious buy signal.
*   **Recent (20-day) Relative Spread Change:** The positive change in relative spread indicates a short-term improvement in RXRX's performance compared to VOO, but starting from a very low base.
*   **Expected Return:**  The extremely negative expected return of -536% is a major concern. This suggests a very pessimistic outlook for long-term investment in RXRX relative to the S&P 500. The large price change of -7.61% in the last market session underscores potential volatility and instability.

### 4. Recent News & Significant Events

*   **[2025-07-13]:** Major business developments, regulatory changes, or market events.
*   **[2025-07-09]:** Analysts discussing RXRX's recent performance and outlook.
*   **[2025-07-11]:** Notable stock volatility.
*   **[2025-07-10]:** Market experts highlight both risks and opportunities.

**Analysis:** Recent news suggests that RXRX is experiencing significant events and volatility, with analysts actively discussing the company's outlook. Investors should closely monitor news and company announcements.

### 5. Recent Earnings Analysis

| 날짜       | EPS    | 매출       |
|------------|--------|------------|
| 2025-05-05 | -0.5   | 0.01 B$    |
| 2024-11-06 | -0.34  | 0.03 B$    |
| 2024-08-08 | -0.4   | 0.01 B$    |
| 2024-05-09 | -0.39  | 0.01 B$    |
| 2025-05-05 | -0.39  | 0.01 B$    |

**Analysis:** RXRX has consistently reported negative Earnings Per Share (EPS) over the analyzed quarters, indicating a lack of profitability. Revenue has been inconsistent, fluctuating between $0.01B and $0.03B.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2025-03-31 | $0.01B  | -47.31%       |
| 2024-12-31 | $0.00B  | -183.62%      |
| 2024-09-30 | $0.03B  | 53.69%        |
| 2024-06-30 | $0.01B  | 36.14%        |
| 2024-03-31 | $0.01B  | 17.23%        |

**Capital and Profitability:**

| Quarter    | Equity  | ROE       |
|------------|---------|-----------|
| 2025-03-31 | $0.93B  | -21.68%   |
| 2024-12-31 | $1.03B  | -17.29%   |
| 2024-09-30 | $0.52B  | -18.27%   |
| 2024-06-30 | $0.58B  | -16.69%   |
| 2024-03-31 | $0.40B  | -22.78%   |

**Analysis:**

*   **Revenue and Profitability:** Revenue is inconsistent, and profit margins fluctuate significantly. Recent quarters show negative profit margins, which is concerning.
*   **Capital and Profitability:** Equity has fluctuated, and Return on Equity (ROE) is consistently negative, indicating the company is not generating profits from its equity.

### 7. Overall Summary

Recursion Pharmaceuticals Inc. (RXRX) is facing significant challenges. The company has substantially underperformed the S&P 500, reports consistent losses, and experiences high volatility.  While the MRI indicates low market risk, the extremely negative expected return suggests a very pessimistic outlook for the stock's long-term performance relative to the market. Recent news indicates potential significant changes and analyst scrutiny. The company needs to demonstrate improved profitability and revenue growth to instill investor confidence. The recent price drop emphasizes the risk associated with this stock.
